Chemical Structure : AZD3965
CAS No.: 1448671-31-5
Catalog No.: PC-43178Not For Human Use, Lab Use Only.
AZD3965 is a potent, selective, orally bioavailable monocarboxylate transporter 1 (MCT1) inhibitor with binding IC50 of 1.6 nM, displays 6-fold selectivity over MCT2 and does not inhibit MCT3 or MCT4.
Packing | Price | Stock | Quantity |
---|---|---|---|
5 mg | $118 | In stock | |
25 mg | $318 | In stock | |
100 mg | $628 | In stock | |
500 mg | Get quote |
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
AZD3965 is a potent, selective, orally bioavailable monocarboxylate transporter 1 (MCT1) inhibitor with binding IC50 of 1.6 nM, displays 6-fold selectivity over MCT2 and does not inhibit MCT3 or MCT4; inhibits both lactate efflux and influx into cells and causes an increase in glycolysis and an upregulation of glycolytic enzymes in SCLC and gastric cancer cell lines; reduces tumor growth and increases intratumor lactate in vivo, enhances radiosensitivity by reducing lactate transport.
Solid Tumors
Phase 1 Clinical
M.Wt | 515.506 | |
Formula | C21H24F3N5O5S | |
Appearance | Solid | |
Storage |
|
|
Solubility |
DMSO: ≥ 36 mg/mL |
|
Chemical Name/SMILES |
Thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione, 5-[[(4S)-4-hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-methylethyl)-6-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]methyl]- |
1. Polański R, et al. Clin Cancer Res. 2014 Feb 15;20(4):926-937.
2. Bola BM, et al. Mol Cancer Ther. 2014 Dec;13(12):2805-16.
3. Hong CS, et al. Cell Rep. 2016 Feb 23;14(7):1590-1601.
4. Beloueche-Babari M, et al. Cancer Res. 2017 Nov 1;77(21):5913-5924.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright